The primary purpose of this study is to evaluate the efficacy of alogliptin 25 milligram (mg)
once daily compared to placebo when administered as monotherapy, or when added onto a
background of metformin alone, insulin alone, or a combination of metformin and insulin, as
measured by the glycosylated hemoglobin (HbA1c) change from Baseline at Week 26 in pediatric
participants with type 2 diabetes mellitus (T2DM).